The number of Norwegian patients increased in 2023
Docrates Cancer Center has been treating Finnish and international patients in Helsinki for more than 15 years. In 2023, the...
Read moreMon-Thu 8-18, Fri 8-16
In January 2017, we were the first health care provider in Finland to use 177-lutetium-PSMA isotope therapy in the treatment of advanced prostate cancer, which enables destroying metastases outside the bones efficiently without any severe adverse effects.
Before the treatment, we carry out a diagnostic PET scan using F-PSMA tracers to ensure that 177-lutetium-PSMA uptake occurs in the metastases.
177-lutetium-PSMA therapies are administered intravenously, and its their most common side effect is a dry mouth. Depending on the individual, the treatment is typically performed 2–6 times approximately every 4–6 weeks (177-lutetium-PSMA).
The multidisciplinary team in charge of peptide-receptor therapies at Docrates Cancer Center is led by Chief Physician in Nuclear Medicine Jukka Kemppainen.
The VISION study results* were presented in ESMO2021 conference: the results showed that treatment with 177-lutetium-PSMA significantly improved overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.
*Publiced in NEJM September 2021
Docrates Cancer Center has been treating Finnish and international patients in Helsinki for more than 15 years. In 2023, the...
Read moreDocrates Cancer Center joined forces with Medanta, a pioneer in healthcare workwear, to create a more functional workwear collection for...
Riikka Talsi, M.Sc. (Tech), who defended her doctoral thesis at Aalto University School of Science, Department of Industrial Engineering and...
Cancer. The word alone makes the heart beat faster and fills people's minds with questions. What if I have cancer?...
Contact us!
Mon-Thu 8:00-18:00, Fri 8:00-16:00